Ashvattha Therapeutics to Present at ARVO, Retina World Congress, and AOS Annual Meeting


Presentations to highlight updated Phase 2 subcutaneous migaldendranib (MGB) data for wet AMD and DME Presentations to highlight updated Phase 2 subcutaneous migaldendranib (MGB) data for wet AMD and DME

Follow this link:
Ashvattha Therapeutics to Present at ARVO, Retina World Congress, and AOS Annual Meeting

Related Posts